Table 5.

Top 10 cited documents of biosimilars research. Scopus 2004–2016

Rank	Title	Year	Journal name	Cited by	Type of document
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update	2014	Annals of the Rheumatic Diseases	962	Article
2	2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours	2011	European Journal of Cancer	498	Article
3	Biopharmaceutical benchmarks 2014	2014	Nature Biotechnology	275	Article
4	A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study	2013	Annals of the Rheumatic Diseases	269	Article
5	A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study	2013	Annals of the Rheumatic Diseases	250	Article
6	Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars	2012	Nature Reviews Drug Discovery	215	Review
7	PEG-modified biopharmaceuticals	2009	Expert Opinion on Drug Delivery	201	Review
8	The challenge of biosimilars	2008	Annals of Oncology	178	Review
9	Sublingual immunotherapy: World Allergy Organization position paper 2013 update	2014	World Allergy Organization Journal	172	Review
10	Biosimilars: What clinicians should know	2012	Blood	158	Review